Mineralys Therapeutics, Inc. Common Stock
MLYSMineralys Therapeutics, Inc. (MLYS) is a biopharmaceutical company focused on developing therapies for cardiovascular and metabolic diseases. The company utilizes proprietary technology to develop targeted treatments aimed at addressing unmet medical needs, with a particular emphasis on hyperkalemia. Mineralys aims to advance innovative solutions to improve patient outcomes in these therapeutic areas.
Company News
Mineralys Therapeutics presented clinical data for lorundrostat at ASN Kidney Week 2025, demonstrating promising results in reducing blood pressure and albuminuria in chronic kidney disease patients. The company plans to file a New Drug Application with the FDA in late 2025 or early 2026.
Two healthcare stocks, Precigen and Mineralys Therapeutics, have seen significant stock price increases recently due to FDA approval and promising clinical trial results in rare disease treatment and hypertension medication development.
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minerals Intl posted quarterly adjusted earnings of 5 cents per share, missing market estimates of 26 cents per share. The company’s quarterly sales came in at $341.70 million versus expectations of $357.90 mi...
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
